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ABSTRACT
Objectives: To analyse coronary heart disease (CHD)
mortality and risk factor trends in the West Bank,
occupied Palestinian territory between 1998 and 2009.
Design: Modelling study using CHD IMPACT model.
Setting: The West Bank, occupied Palestinian
territory.
Participants: Data on populations, mortality, patient
groups and numbers, treatments and cardiovascular
risk factor trends were obtained from national and
local surveys, routine national and WHO statistics, and
critically appraised. Data were then integrated and
analysed using a previously validated CHD model.
Primary and secondary outcome measures:
CHD deaths prevented or postponed are the main
outcome.
Results: CHD death rates fell by 20% in the West
Bank, between 1998 and 2009. Smoking prevalence
was initially high in men, 51%, but decreased to
42%. Population blood pressure levels and total
cholesterol levels also decreased. Conversely, body
mass index rose by 1–2 kg/m2 and diabetes increased
by 2–8%. Population modelling suggested that more
than two-thirds of the mortality fall was attributable to
decreases in major risk factors, mainly total
cholesterol, blood pressure and smoking.
Approximately one-third of the CHD mortality
decreases were attributable to treatments, particularly
for secondary prevention and heart failure. However,
the contributions from statins, surgery and
angioplasty were consistently small.
Conclusions: CHD mortality fell by 20% between
1998 and 2009 in the West Bank. More than two-third
of this fall was due to decreases in major risk factors,
particularly total cholesterol and blood pressure. Our
results clearly indicate that risk factor reductions in
the general population compared save substantially
more lives to specific treatments for individual
patients. This emphasizes the importance of
population-wide primary prevention strategies.
INTRODUCTION
The occupied Palestinian territory (oPt) com-
prises the Gaza Strip and the West Bank
including East Jerusalem. Some 46% of the
Palestinian population of 3.8 million are
younger than 15 years while only 3% are older
than 65 years. However, the number of older
people is increasing gradually and the popula-
tion is slowly ageing. The Palestinians are also
undergoing rapid epidemiological transition.
Communicable diseases of childhood have
already been controlled with effective immun-
isation programmes, and poliomyelitis has
been eradicated. However, non-communicable
diseases have now overtaken communicable
diseases as the main causes of mortality.1 Thus,
cardiovascular disease (CVD) and cancer are
now the major causes of morbidity and mortal-
ity in the oPt.2 The Ministry of Heath (MOH)
recently reported that 25% of all deaths are
due to cardiovascular diseases in 2010, fol-
lowed by cerebrovascular diseases (12%),
cancer (11%) and diabetes (6%).3 Increasing
levels of adverse risk factors such as diabetes,
obesity and physical inactivity have been
repeatedly documented.4 5
Chronic disease death rates are actually
decreasing in the developed world (Western
Europe, North America, Australia and New
Zealand). However, mortality is increasing in
the developing countries. It is predicted that by
2020, CVD deaths will exceed infectious and
parasitic disease deaths in all regions except
for sub-Saharan Africa.6 Furthermore, the
Eastern Mediterranean region has been recog-
nised as a hot spot for diabetes and CVD, yet
local data to inform policy is severely limited.
KEY POINTS
▪ CHD mortality fell by 20% between 1998 and
2009 in the West Bank.
▪ More than two-third of this fall was due to
decreases in major risk factors, particularly total
cholesterol, and blood pressure.
Abu-Rmeileh NME, Shoaibi A, O’Flaherty M, et al. BMJ Open 2012;2:e001061. doi:10.1136/bmjopen-2012-001061 1
Open Access Research
 group.bmj.com on August 26, 2012 - Published by bmjopen.bmj.comDownloaded from 
The IMPACT coronary heart disease (CHD) model
was developed to quantify recent trends in CHD mortal-
ity, in order to help maximise the effective use of exist-
ing information and resources to develop appropriate
policies and strategies. This study aims to adopt the
IMPACT CHD model to the Palestinian context, namely
the West Bank population, in order to help explain
recent changes in CHD mortality.
METHODS
A validated version of the IMPACT CHD mortality model
was further modiﬁed and updated to suit the countries in
the Middle East and speciﬁcally the oPt. The IMPACT
model was previously validated in many developed coun-
tries7–10 and in one middle-income country (China).11
Palestinian data on risk factors levels and current
uptake levels of evidence-based treatments were identi-
ﬁed by extensive searches for published or unpublished
data and complemented with speciﬁcally designed
surveys. All data sources were critically appraised by the
local research team and the results are presented in the
appendix. The data needed for the analysis were avail-
able for men and women aged 25–75 years in the West
Bank, occupied Palestinian territory for the period
1998–2009 with some age limitations as described in the
appendix.
The speciﬁc data items used to populate the model
included: (1) Patient numbers in speciﬁc CHD groups
(myocardial infarction (MI), congestive heart failure
and chronic angina pectoris), (2) uptake of speciﬁc
medical and surgical treatments, (3) population trends
in major cardiovascular risk factors (smoking, total chol-
esterol, systolic blood pressure, body mass index (BMI),
diabetes and physical inactivity).
The main output of the model is the number of
deaths prevented or postponed attributed to the
changes in speciﬁc treatments and/or risk factor levels.
Identification and assessment of relevant data
Information on the West Bank population demographic
changes was obtained and validated for the ﬁrst year from
1997 census-based projections and 2007 census-based pro-
jections for the ﬁnal year by the Palestinian Central Bureau
of Statistics (PCBS).12 Numbers of deaths for both years were
obtained from the Health Information Management
Centre—Palestinian Ministry of Health (MOH). Population
risk factors trend data for the year 1998 were obtained from
two epidemiological studies conducted in the rural and
urban areas of Ramallah governorate in the West Bank.
These were the only available published epidemiological
studies in the West Bank for that period. They covered a
rural and an urban site that were prototypic of many West
Bank villages and urban sites.4 13
CHD numbers of hospital admissions in addition to treat-
ment uptake were obtained from our treatment uptake
survey conducted in 2009 which included four hospitals
in the north, centre and south of the West Bank. The
number of patients undergoing coronary artery bypass
grafting and angioplasty were obtained from records in
the two hospitals providing this service in the West Bank.
The prevalence of angina, heart attack survivors and
congestive heart failure in the community were each esti-
mated on the basis of national health surveys and treat-
ment uptake surveys. Information on treatment uptake
in the community was also checked by eliciting expert
opinion from practising clinicians.
The efﬁcacy of therapeutic interventions was based on
recent meta-analyses and randomised controlled trials.
The Mant and Hicks14 approach was used to correct for
polypharmacy.
Change in CHD deaths
First, the number of CHD deaths expected in 2009 was cal-
culated by indirect age standardisation based on the
assumption that 1998 death rates had persisted
unchanged until 2009. The number of CHD deaths actu-
ally observed in 2009 was then subtracted. The difference
between the two represents the fall in CHD deaths (the
number of deaths prevented or postponed) that the
model needed to explain.
Mortality changes attributed to risk factor trends
The number of deaths prevented or postponed from
changes in risk factors was estimated using two
approaches. The regression β coefﬁcients approach was
used to quantify the population mortality impact of
change in those speciﬁc risk factors, measured as con-
tinuous variables (blood pressure, total cholesterol and
BMI). The second approach, population-attributable
risk fraction, was employed for categorical variables—
diabetes, physical inactivity and smoking:
PAR ¼ Prevalence ðRelative risk  1ÞðPrevalence  ðRelative risk  1ÞÞ þ 1
PAR calculation was stratiﬁed by age and sex. Details of
model methodology have been published previously7 and
worked examples are shown in the appendix.
Estimating the contribution of medical and
surgical treatments
The model aimed to include all medical and surgical treat-
ments in 1998 (the base year) and 2009 (the ﬁnal year).
Treatment uptake data were not available for the year 1998
and thus the data included in the model for this year was
estimated after consultation with cardiologists and experts
working in hospital and community at that time.
The mortality reduction for each treatment for the
number of patients in each group, stratiﬁed by age and
sex, was calculated as the age-speciﬁc case death in that
group multiplied by the relative mortality reduction
reported in published meta-analyses multiplied by the
treatment uptake (the proportion of patients receiving
that speciﬁc treatment, appendix).
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Case- death data were obtained from large, unselected,
population-based patient cohorts. The survival beneﬁt
over a 1-year time interval was used for all treatments.
Treatment overlaps
Potential overlaps between different groups of patients
were identiﬁed and appropriate adjustments were made.
Patients group calculations and assumptions are detailed
in the appendix.
Treatment adherence
Adherence (deﬁned as the proportion of treated
patients actually taking therapeutically effective levels of
the prescribed medication) was assumed to be 100%
among hospital patients, 70% among all symptomatic
community patients and 50% among asymptomatic com-
munity patients, based on the literature.15
Sensitivity analyses
Because of the uncertainties surrounding some of the
values, multiway sensitivity analyses using the Brigg’s ana-
lysis of extremes method was used.16
Model validation: comparison with observed
mortality falls
The model estimate for the changes in deaths attributed
to all treatments plus all risk factor changes was summed
for men and women in each speciﬁc age group. The
model ﬁt was then compared with the observed change in
mortality for that group.
RESULTS
Between 1998 and 2009 CHD mortality in the West Bank
fell by 20%. This resulted in approximately 125 fewer
CHD deaths compared with the expected number of
CHD deaths in 2009 if 1998 death rate had persisted
unchanged (table 1).
The reduction in CHD mortality among women
(35%) was twice as large as the 19% reduction observed
among men. The CHD mortality reduction was seen in
all age groups with particularly large reductions being
observed among those aged 45–54 years, men (24%)
and women (49%).
Major CHD risk factors
Changes in cardiovascular risk factors included in the
model were together estimated to prevent or postpone
approximately 80 deaths in 2009 (minimum estimate 75
and maximum estimate 140), which represented
approximately 66% of the total CHD mortality fall
(ﬁgure 1).Table 2 presents changes in the selected risk
factors and the attributed deaths. Changes in risk factors
were complex: reduction in total cholesterol (mean
reduction 0.34mmol/l in men and 0.22 mmol/l in
women), blood pressure (5.27 mm Hg in men and
0.01 mm Hg in women) and in smoking prevalence
(11.5% in men and 2.2% in women). These changes
together prevented or postponed approximately 125
deaths (table 2). A total fall of 40% in CHD deaths were
thus attributable to cholesterol reduction (minimum
38% and maximum 77%), and 36% to blood pressure
reduction (minimum 30% and maximum 50%) and
33% to smoking reduction (minimum 22% and
maximum 49%). However, an additional 45 deaths were
attributable to adverse trends (ﬁgure 2). Mainly an
increase in diabetes prevalence (8.5% in men and 2% in
women) generated approximately 30 additional deaths.
The mortality effects of increases in physical inactivity
and mean BMI were relatively modest (table 2).
Table 1 Population sizes and coronary heart disease death rates in the West Bank, 1998 and 2009
Age groups
25–34 35–44 45–54 55–64 65–74 Total
Men
Population in 1998 132084 80434 41727 28653 19524 302422
Population in 2009 177873 132945 86399 41984 21619 460820
Deaths in 1998 (number) 9 21 57 101 130 318
Deaths in 2009 (number) 11 30 89 131 133 394
Death rates per 100000 in 1998 6.4 26.1 135.4 350.7 665.8 105.2
Death rates per 100000 in 2009 6.2 22.8 103.4 311.2 616.7 85.5
Percentage of change (crude) 0 −12.6 −23.6 −11.3 −7.4 −19
Women
Population in 1998 125493 76747 45711 36038 24445 308434
Population in 2009 170942 127590 80883 43693 28424 451532
Deaths in 1998 (number) 5 9 22 59 107 202
Deaths in 2009 (number) 5 11 20 51 105 192
Death rates per 100000 in 1998 3.6 11.1 48.1 162.3 437.7 65.5
Death rates per 100000 in 2009 3.1 8.9 24.7 116.0 370.6 42.5
Percentage of change (crude) 0 −19.8 −48.6 −28.6 −15.3 −35
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Medical and surgical treatments
Medical and surgical treatments together prevented or
postponed approximately 35 deaths in 2009 (minimum
estimate 20 and maximum estimate 108; ﬁgure 3). The
total treatments thus accounted for approximately 29%
(minimum 17% and maximum 82%) of the total CHD
mortality reduction (table 3). Secondary prevention fol-
lowing acute MI explained over 7% (minimum 3% and
maximum 25%) of deaths prevented or postponed (with
ACE inhibitors, aspirin and β-blockers and β-blockers
being the main contributors in this group; table 3).
Smaller contributions came from chronic angina treat-
ment (6%, minimum 5% and maximum 11%) and
heart failure treatment in the community (5%,
minimum 3% and maximum 10%) and hypertensive
treatment in the community (4%, minimum 1% and
maximum 19%). Secondary prevention postrevasculari-
sation had a very modest effect on CHD mortality reduc-
tion with a contribution of 2% (minimum 1% and
maximum 5%; table 3).
Validation and model fit
In summary, when including all risk factor and treat-
ment data, the model explained approximately 95% of
the total CHD mortality reduction observed in the West
Bank population between 1998 and 2009. The remain-
ing 5% was unexplained and might reﬂect other,
unmeasured factors. The model estimates of deaths were
reasonably consistent with the observed deaths for
almost all age groups. Overall, the model ﬁt was better
for men than for women. However, in the age group
45–54 the model overestimated deaths in men and
women (table 4). Moreover, irrespective of whether best
minimum or maximum estimates were used, the relative
contributions remained relatively consistent.
DISCUSSION
CHDs mortality decreased by 20% in the West Bank, oPt
between 1998 and 2009. Almost two-thirds of this reduc-
tion was attributable to changes in major risk factors
and approximately one-third was explained by medical
and surgical treatments. The recent mortality trends
observed in the West Bank were thus characterised by
reductions in CHD mortality similar to those observed
in the developed rather than developing countries.
Other studies have documented similar reductions in
CHD mortality in Europe, North America and New
Zealand especially since the 1980s.7 8 17 18
The biggest CHD mortality reductions attributable to
changes in major risk factors came from declines in
total cholesterol and smoking, and also blood pressure
in men. Interestingly, the implementation efforts of an
antismoking law in 2005 might have contributed to the
substantial declines in smoking prevalence.19 20
However, the increasing Westernisation of diet, par-
ticularly junk food and soda represent an ominous
future threat. Furthermore, diabetes, obesity and phys-
ical inactivity increased substantially between 1998 and
2009.21–23 In the year 1998, the prevalence of obesity was
49% for women and 30% for men aged 35–64 years
old.24 Since then, the prevalence of obesity has
increased mainly among men.25 26 The increase in dia-
betes prevalence generated approximately 30 additional
CHD deaths. Rising diabetes and obesity, especially
among men, represents a public health priority.
Figure 1 Coronary heart
disease deaths prevented or
postponed by treatment and risk
factor changes in the West Bank
population between 1998 and
2009.
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Table 2 Deaths attributable to population risk factor changes in the West Bank between 1998 and 2009
Risk factors
Risk factor
levels
Absolute change in
risk factor 1998–2009
Relative risk (or β
coefficient)
Deaths prevented or postponed
1998 2009
Best
estimate
Minimum
estimate
Maximum
estimate
Proportion of
overall deaths (%)
Cholesterol (total) (mmol/l) 49 46 94 −40.3
Cholesterol (men) 5.37 5.03 0.34 βετα 0.65
Cholesterol (women) 5.25 5.03 0.22 βετα 0.65
Smoking (total) (%) 40 26 59 −32.5
(% men smoking) 51.5 40 11.5
(% women smoking) 5.5 3.3 2.2
Body mass index (BMI) (total) (kg/m2) −2 −2 −5 −2
BMI (men) 26.95 30.88 −3.93 βετα 0.02
BMI (women) 29.12 30.99 −1.87 βετα 0.02
Diabetes (total) % −32 −27 −60 26.2
Percentage of diabetes (men) 9.1 17.6 −8.5 2
Percentage of diabetes (women) 12.4 14.4 −2 2
Population systolic blood pressure (BP) (total) mm Hg 43 39 84 −35.6
Population BP (men) 125.57 120.3 5.27 βετα 0.053
Population BP (women) 118.44 118.45 −0.01 βετα a0.053
Population BP after adjustment for hypertension treatments 38 37 61 −31.5
Physical inactivity −12 −8 −17 9.7
Percentage of physical
inactivity men
79.3 91.3 12
Percentage of physical
inactivity women
87.9 93 5.1
Estimated total risk factor effects 81 73 138 −66.5
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Effective evidence-based interventions exist and should
be considered, notably junk-food taxes, labelling and
reformulation issues and advertising bans.27 28
The recently developed Palestinian non-communicable
diseases (NCDs) strategy adopted an integrated app-
roach encompassing promotion, prevention and control
programmes. Population-based multisectoral effective
evidence-based interventions were clearly indicated to
control diabetes and promote physical activity such as
health promotion, ﬁscal measures, market control and
community participation. Yet a clear vision and scope of
implementation are still evolving.29
Modern medical treatments accounted for approxi-
mately 30% of the CHD mortality reduction. The scale
of effect is similar to that reported in studies using the
same methodology in Iceland, Sweden and Finland9 but
lower than the 45–50% reported for North America30
and Europe.8 10 The biggest contributions came from
aspirin and community-based medications for secondary
prevention, chronic angina and heart failure. Treatment
uptakes were generally mediocre and need to be
improved. However, such treatments create challenges
for health providers in terms of identifying patients, pro-
viding medications and ensuring their long-term
compliance.
Data on patient groups and treatment uptake levels
were scarce. Such data were not available at the national
or the hospital level. The required information was
therefore collected directly from the hospital patients’
records to be utilised in this study. Furthermore, the
uptake levels were not consistent among different hospi-
tals and sometimes between physicians. These two ﬁnd-
ings therefore highlight a lack of standardised
healthcare provision and important gaps in the NCD
health information system.
Modelling strengths and limitations
The modelling approach used in the study was com-
prehensive, it synthesised all the key risk factors and
treatment options to help quantify changes in CHD mor-
tality. Additionally, the model used rigorous sensitivity
analyses to systematically examine the potential inﬂuence
of uncertainties in the data (quality and sources) and
model assumptions, and hence quantify the potential
maximum and minimum effects of these contributory
factors
This modelling approach also has obvious limitations.
Notably, the extent and quantity of available data on
CHD risk factor trends and treatment uptake.
Furthermore, the model tended to overestimate the
number of deaths averted in almost all age groups, espe-
cially among women. This may reﬂect less precision in
female data. However, the data used in this model was
generally of good quality. Mortality data were obtained
from MOH death registry. Death registry data were eval-
uated in previous studies as medium quality based on
the WHO criteria.31 The demographic information was
obtained from census data, and the risk factor trends
were obtained from well-designed epidemiological
studies and national PCBS, MOH and WHO surveys.
Treatment uptake and patient group data were obtained
from an extensive hospital-based survey conducted in
2009. Very scarce data available on treatment uptake
were also obtained. However, researchers had to
conduct additional surveys to get the timely, accurate
data required by the model. Certain assumptions were
needed to ﬁll in the gaps for missing information. For
instance, assumptions were made for the small group
aged 65–74 years where risk factor information were not
available. Assumption on treatment uptake at the start-
ing point was also based on expert opinions working in
the system for more than 10 years. Estimates of treat-
ment uptake were collated from international and
Figure 3 Coronary heart disease deaths prevented or
postponed attributable to specific treatments in Palestine
1998–2009: Sensitivity analysis (▪, best estimate; bars
indicate minimum and maximum estimates).
Figure 2 Coronary heart disease deaths prevented or
postponed attributable to specific risk factor changes in
Palestine 1998–2009: Sensitivity analysis (▪, best estimate;
bars indicate minimum and maximum estimates).
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regional literature then validated with the expert opi-
nions. The generalisation of efﬁciency estimates from
meta-analysis of controlled clinical trials to effectiveness
in clinical practice in the West Bank setting were clearly
optimistic, and may have resulted in an overestimate of
the true treatment beneﬁts.
All these assumptions are transparent, being systematic-
ally detailed in the appendix, supported by local expert
opinions and literature from the region and included in
the sensitivity analyses. By good luck, the overall model ﬁt
approached 100%. However, it should be noted that ﬁt
within speciﬁc age groups was much less perfect.
Public health implications
CHD mortality fell by 20% between 1998 and 2009 in
the West Bank, oPt. More than two-third of this fall was
Table 3 Deaths prevented or postponed by medical and surgical treatments in the West Bank in 2009
Coronary heart disease deaths
prevented or postponed
Proportion of
overall deaths
prevented or
postponed (%)Treatments
Patients
eligible
Treatment
uptake (%)
Best
estimate
Minimum
estimate
Maximum
estimate
Acute myocardial infarction 489 2 1 6 −1.9
Hospital resuscitation 0.06 0 0 1 −0.3
Thrombolysis and aspirin
Aspirin alone 0.90 5 2 9 −3.8
Thrombolysis alone 0.39 3 1 6 −2.4
β-Blockers 0.58 1 0 2 −0.6
ACE inhibitors 0.44 1 0 2 −1
Secondary preventionpostinfarction 2266 9 4 30 −7.4
Aspirin 0.483 4 1 9 −2.9
β-Blockers 0.388 4 1 11 −3.6
Aspirin and β-blockers 0.415 4 1 10 −3.4
ACE inhibitors 0.472 5 2 13 −4.2
Statins 0.046 0 0 1 −0.4
Warfarin 0.100 1 0 3 −0.9
Rehabilitation 0.483 1 0 3 −0.9
Secondary
preventionpostrevascularisation
208 2 0 6 − 1.9
Angina 7 6 13 −5.7
Coronary Artery Bypass
Grafting surgery (2004–2005)
208 1 6 3 10 −4.6
Aspirin in the community 22180 0.47 15 13 40 −12.7
Statin in the community 22180 0.46 20 11 50 −16.8
Unstable angina 489 1 2 9 −1.1
Heart failure 2811
Hospital patients 468 −2 −1 −8 −1.5
Community patients 2342 −7 −4 −4 −5.4
Hypertension treatments −5 −2 −23 −4.1
Total treatment effects 35 20 108 29
Table 4 Model validation: estimated versus observed changes in coronary heart disease (CHD) deaths between 1998
and 2009
Age groups
25–34 35–44 45–54 55–64 65–74 Total
Men
Estimated fall in CHD deaths 11 35 117 147 144 454
Observed fall in CHD deaths 11 30 89 131 133 394
Discrepancy 0 −5 −28 −16 −11 −60
Estimated fall/ observed fall in CHD deaths (%) 100 117 131 112 108 115
Women
Estimated fall in CHD deaths 6 14 39 71 124 254
Observed fall in CHD deaths 5 11 20 51 105 192
Discrepancy −1 −3 −19 −20 −19 −62
Estimated fall/observed fall in CHD deaths (%) 120 127 195 139 118 132
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due to changes in major risk factors mainly total choles-
terol, blood pressure and smoking.
Our results clearly indicate that risk factor improve-
ments in the general population saved substantially
more lives than speciﬁc treatments for individual
patients. This emphasizes the importance of population-
wide primary prevention strategies. Such strategies
should also emphasize the risk factors which had a nega-
tive effect on the reduction of CHD in the model espe-
cially, diabetes, BMI and increased levels of physical
inactivity. The Palestinian policy and strategic plan for
NCD had focused on health diet and physical activity as
its second and third policy objectives (MOH).32
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